Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Assessor- and Patient-blind, Multicentre, Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose in Improving Outcomes in Iron Deficient Non-anaemic Patients with Restless Legs Syndrome

Next Previous
Trial Profile

A Randomised, Assessor- and Patient-blind, Multicentre, Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose in Improving Outcomes in Iron Deficient Non-anaemic Patients with Restless Legs Syndrome

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jul 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Iron metabolism disorders; Restless legs syndrome
  • Focus Therapeutic Use
  • Sponsors Vifor

Most Recent Events

  • 23 Jun 2017 Primary endpoint of change in IRLS score from baseline to week 4 has not been met, according to results published in the Movement Disorders.
  • 23 Jun 2017 Results published in the Movement Disorders
  • 02 Mar 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top